Hedeker Wealth LLC increased its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,996 shares of the biopharmaceutical company’s stock after acquiring an additional 468 shares during the period. Hedeker Wealth LLC’s holdings in Bristol-Myers Squibb were worth $1,058,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Blue Chip Partners Inc. grew its position in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the last quarter. Keel Point LLC grew its position in Bristol-Myers Squibb by 0.3% during the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 18 shares during the last quarter. Staley Capital Advisers Inc. grew its position in Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 24 shares during the last quarter. Shayne & CO. LLC grew its position in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 24 shares during the last quarter. Finally, Chilton Investment Co. LLC grew its position in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the last quarter. Institutional investors and hedge funds own 68.97% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Hedeker Wealth LLC Buys 468 Shares of Bristol-Myers Squibb Company (BMY)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/hedeker-wealth-llc-buys-468-shares-of-bristol-myers-squibb-company-bmy/1720917.html.

A number of equities research analysts recently commented on the company. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target on the stock. in a research report on Thursday, September 28th. Finally, Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $64.93.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Company (BMY) opened at $61.14 on Thursday. The company has a market capitalization of $100,231.52, a price-to-earnings ratio of 20.69, a P/E/G ratio of 2.41 and a beta of 1.18. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 EPS. analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.55%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is presently 61.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.